Peter Joyce

Peter Joyce

Company: Grey Wolf Therapeutics

Job title: Chief Executive Officer


ERAP1 Inhibition To Alter Tumor Visibility And Trigger Differentiated T Cell Responses 11:15 am

• Tumor visibility, defined as the level of tumor-specific antigen expression, is shown to strongly correlate with response to checkpoint inhibition and is a vital aspect determining the immunogenicity within the tumor microenvironment • Grey Wolf have developed inhibitors of ERAP1, an aminopeptidase in the antigen presentation pathway that determines which antigens are presented on…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.